HK1251260A1 - Bcl-2家族的異二聚體特異性抗體及其用途 - Google Patents

Bcl-2家族的異二聚體特異性抗體及其用途

Info

Publication number
HK1251260A1
HK1251260A1 HK18110611.8A HK18110611A HK1251260A1 HK 1251260 A1 HK1251260 A1 HK 1251260A1 HK 18110611 A HK18110611 A HK 18110611A HK 1251260 A1 HK1251260 A1 HK 1251260A1
Authority
HK
Hong Kong
Prior art keywords
heterodimers
bcl
family
antibodies specific
antibodies
Prior art date
Application number
HK18110611.8A
Other languages
English (en)
Inventor
Michael H Cardone
Anthony G Letai
Original Assignee
Eutropics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutropics Pharmaceuticals Inc filed Critical Eutropics Pharmaceuticals Inc
Publication of HK1251260A1 publication Critical patent/HK1251260A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK18110611.8A 2008-05-07 2018-08-17 Bcl-2家族的異二聚體特異性抗體及其用途 HK1251260A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5120608P 2008-05-07 2008-05-07

Publications (1)

Publication Number Publication Date
HK1251260A1 true HK1251260A1 (zh) 2019-01-25

Family

ID=41264999

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110611.8A HK1251260A1 (zh) 2008-05-07 2018-08-17 Bcl-2家族的異二聚體特異性抗體及其用途

Country Status (4)

Country Link
US (4) US8168755B2 (zh)
EP (2) EP3284828A1 (zh)
HK (1) HK1251260A1 (zh)
WO (1) WO2009137664A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
EP2742063A1 (en) 2011-08-11 2014-06-18 Yeda Research and Development Co. Ltd. Compositions and methods for modulating apoptosis
CN111856013A (zh) 2012-05-10 2020-10-30 尤特罗皮克斯制药股份有限公司 对癌症的代理功能性诊断测试
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2015017788A1 (en) * 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
US20160018414A1 (en) * 2014-07-21 2016-01-21 The Florida International University Board Of Trustees SAB as a Biomarker for Degenerative Diseases and Therapeutic Sensitivity in Cancers
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
WO2016154380A1 (en) * 2015-03-24 2016-09-29 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CN107995863A (zh) 2015-04-20 2018-05-04 特雷罗药物股份有限公司 通过线粒体分析预测对阿伏西地的应答
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
EP3740757A4 (en) * 2018-01-18 2022-06-15 Eutropics Pharmaceuticals, Inc. PROCEDURE FOR PREDICTING RESPONSE TO AN ANCIENT DRUG
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5981201A (en) * 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
WO1999014321A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
CA2329868A1 (en) 1998-05-18 1999-11-25 Apoptosis Technology, Inc. Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
US20020177692A1 (en) * 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
JP4480674B2 (ja) 2002-12-26 2010-06-16 ザクリトエ アクツィオネルノエ オブシェストヴォ “エフロージェン” コペポーダ種由来の蛍光たんぱく質および該たんぱく質の使用方法
BRPI0408961A (pt) * 2003-04-01 2006-10-31 Monogram Biosciences Inc método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente
US8323987B2 (en) * 2004-02-17 2012-12-04 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
JP5813908B2 (ja) * 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
WO2015017788A1 (en) * 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity

Also Published As

Publication number Publication date
US20120225794A1 (en) 2012-09-06
EP2304047A1 (en) 2011-04-06
US20140234867A1 (en) 2014-08-21
US8168755B2 (en) 2012-05-01
US20180208672A1 (en) 2018-07-26
WO2009137664A1 (en) 2009-11-12
US20090280510A1 (en) 2009-11-12
EP2304047A4 (en) 2012-12-26
EP3284828A1 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
HK1251260A1 (zh) Bcl-2家族的異二聚體特異性抗體及其用途
HK1256622A1 (zh) Il-6的抗體和其用途
IL271270A (en) Antibodies to 6-il and their use
PL2246427T3 (pl) Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
IL232276A0 (en) Antibodies to 6-il and their uses
EP2427479A4 (en) ANTIBODIES AND METHODS OF USE THEREOF
LT2373691T (lt) Anti-fxi antikūnai ir jų panaudojimo būdai
EP2504031A4 (en) ANTI-IL-6 ANTIBODIES AND THEIR USE
ZA201102550B (en) Antibodies that bind to il-18 and methods of purifying the same
IL218763A (en) Anti-gcc antibody molecules, pharmaceutical compositions and methods of use
IL211623A0 (en) Anti-notch2 antibodies and methods of use
IL215795A0 (en) Anti-il-17f antibodies and methods of use thereof
IL215291A0 (en) NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
HK1178917A1 (zh) 抗體及其用途
EP2246430A4 (en) ANTI-ADAM-15 ANTIBODIES AND THEIR USE